LDN-57444 - Ubiquitin C-terminal Hydrolase-L1 (UCH-L1) Inhibitor. CAS# 668467-91-2 Catalog No.:M60204-10S Multiple-dose treatment with BMS-201038 also

Multiple-dose treatment with BMS-201038 also results in dose dependent decrease in triglycerides (71%–87%)

Currently GSK2879552 is in phase I clinical trials targeting Acute Myeloid Leukemia (AML) and Relapsed/Refractory Small Cell Lung Carcinoma

) demonstrates anti-tumor activity in NSCLC EGFR mutant xenograft models

Chemical Name: N-((4

Phase I pharmacokinetic/pharmacodynamic study of MLN8237

LDN-57444 - Ubiquitin C-terminal Hydrolase-L1 (UCH-L1) Inhibitor. CAS# 668467-91-2 Catalog No.:M60204-10S Multiple-dose treatment with BMS-201038 alsoLDN 57444, CAS No. 668467 91 2, is a novel potent and selective inhibitor of ubiquitin C terminal hydrolase L1 (UCH L1) with IC50 ~0. 88 M. It has ~28 fold greater selectivity over UCH L3 (ubiquitin C terminal hydrolase L3). LDN 57444 can increase levels of highly ubiquitinated proteins and decreases ubiquitin proteasome activity. It causes cell death through the apoptosis pathway. LDN 57444s activity leads to dramatic alterations in synaptic protein